Elena Becerra, Inmaculada de la Torre, Geraldine Cambridge

Rheumatoid arthritis and B cell depletion therapy

Relationships between expression of B-cell activating factor binding receptors and patterns of clinical relapse

• Broschiertes Buch

Produktbeschreibung

Rheumatoid arthritis is a chronic systemic inflammatory disease with joint involvement and extra-articular features. B cell depletion therapy based on Rituximab in rheumatoid arthritis was first used at University College London in 1998, describing two patterns of disease relapse after a good response to Rituximab: either occurring coincident with B-cell return (concordant relapse) or 'delayed' occurring months after B-cell return (discordant relapse). B-cell activating factor (BAFF) and its receptors (BARR-receptor, TACI and BCMA) play an esential role in B-cell maturation, homeostasis and survival. The current thesis hypothesises that the two different patterns of relapse after B cell repopulation following Rituximab could be explained by differences in the expression of BAFF and its binding receptors.

Produktdetails

• Verlag: Scholar's Press
• Seitenzahl: 164
• Erscheinungstermin: 19. Februar 2018
• Englisch
• Abmessung: 220mm x 150mm x 10mm
• Gewicht: 262g
• ISBN-13: 9786202307437
• ISBN-10: 6202307439
• Artikelnr.: 51638411

Autorenporträt

Dr Elena Becerra Fernández currently works as a rheumatologist and clinical researcher at a local hospital in Spain. She previously worked as a research fellow at University College London, UK, contributing to several studies in rheumatoid arthritis and B cell depletion therapy, and developing her thesis project and various scientific articles.